arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Lineage Cell Therapeutics, Inc.

LCTX
$1.10 ▼ -0.04 (-3.93%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
18 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
7
Health
Poor
Bearish
auto_awesome

Analytical Summary

Lineage Cell Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $253.1M
Dividend Yield
Revenue Growth 53.2%
Op. Margin -251.6%
ROIC -75.9%
FCF / Share $-0.08
Trailing P/E
Price / Book 6.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$14.56M
↑ +53.2%
Net Income Profit after all expenses
$-63.53M
↓ -241.4%
Operating Margin Operating profit as % of sales
-251.6%
↓ -11.3% 0th
FCF / Share Free cash flow per share
$-0.08
↑ +28.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
5
Financial Health
4
Cash Quality
33

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters